Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 11-12/2002

01-12-2002 | Original Article

Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues

Authors: Akihiro Tsuboi, Yoshihiro Oka, Keiko Udaka, Masaki Murakami, Tomoki Masuda, Akiko Nakano, Hiroko Nakajima, Masaki Yasukawa, Akio Hiraki, Yusuke Oji, Manabu Kawakami, Naoki Hosen, Tatsuya Fujioka, Fei Wu, Yuki Taniguchi, Sumiyuki Nishida, Momotaro Asada, Hiroyasu Ogawa, Ichiro Kawase, Haruo Sugiyama

Published in: Cancer Immunology, Immunotherapy | Issue 11-12/2002

Login to get access
Metadata
Title
Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues
Authors
Akihiro Tsuboi
Yoshihiro Oka
Keiko Udaka
Masaki Murakami
Tomoki Masuda
Akiko Nakano
Hiroko Nakajima
Masaki Yasukawa
Akio Hiraki
Yusuke Oji
Manabu Kawakami
Naoki Hosen
Tatsuya Fujioka
Fei Wu
Yuki Taniguchi
Sumiyuki Nishida
Momotaro Asada
Hiroyasu Ogawa
Ichiro Kawase
Haruo Sugiyama
Publication date
01-12-2002
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 11-12/2002
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-002-0328-9

Other articles of this Issue 11-12/2002

Cancer Immunology, Immunotherapy 11-12/2002 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine